TAAR1 and psychotic disorder: Preclinical data suggest TAAR1 agonists may be uniquely positioned to target the presynaptic mechanisms underlying dopamine synthesis capacity dysfunction in psychosis and modulate glutamatergic circuit alterations associated with core symptoms of schizophrenia.